As previously announced, Valneva SE (NASDAQ: VALN) said it would not invest in further COVID-19 vaccine development, VLA2001, without a new partnership. However, it is completing the remaining clinical studies and submissions.
Last week, the Committee for Medicinal Products for Human Use of the European Medicines Agency backed VLA2001 approval in adults as a booster dose after at least seven months following primary vaccination with VLA2001 (homologous booster dose) or with an adenoviral vector COVID-19 vaccine (heterologous booster dose).
Related: Valneva Touts Additional Positive Heterologous Booster Data From COVID-19 Vaccine Study.
In Phase 3 Study COV-Compare study, neutralizing antibodies six months after the second dose of the primary vaccination with VLA2001 was non-inferior compared to the active comparator AZD1222, better known as AstraZeneca Plc’s (NASDAQ: AZN) Covishield.
The fold decline of neutralizing antibodies over six months after a second vaccination with VLA2001 was similar to the active comparator and less pronounced than other licensed COVID-19 vaccines.
Additionally, VLA2001-304 Phase 3 study in older adults showed that VLA2001 was well tolerated when administered as a two-dose or three-dose immunization.
In this age group, a two-dose vaccination with VLA2001 was inferior regarding geometric mean titers and seroconversion rates compared to younger adults.
After two doses, immunogenicity in older adults was at a level that could correlate with 60-70% vaccine efficacy against original SARS-CoV-2. A third dose further increased immunogenicity with a vaccine efficacy of over 90%.
Price Action: VALN shares traded flat at $12.29 on the last check Thursday.
Photo Via Wikimedia Commons
Don’t miss real-time alerts on your stocks – join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
This article Valneva Shares Updated Data From Now Shelved COVID-19 Vaccine Development Program originally appeared on Benzinga.com
.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Related Quotes
Health regulators say it's the first over-the-counter test that can detect Influenza A and B as well as COVID.
Reata won Food and Drug Administration approval for its neurological disease treatment and RETA stock almost tripled Wednesday.
Budweiser Brewing Co APAC, Asia's largest beer company by sales, said on Thursday it will expand into more Chinese cities with its premium products as it sees a rebound in demand after the country lifted its COVID-19 curbs. In December, China suddenly dropped its strict three-year-old zero-COVID policy, which had battered business at bars and restaurants, where Budweiser does a disproportionate share of its sales. Budweiser said its overall China volumes fell 3% last year, and its market share shrank by 44 bps.
You take videos with your phone to capture life’s moments. Whether you are recording a piano recital, the construction of a sandcastle or your dog’s antics, video is a great way to hold onto a memory. A California startup company now has a way to enhance your videos, making them immersive and more engaging. Wist Labs created a virtual reality (VR) app that lets you explore a video environment. With the app and a VR headset, you can revisit videos and ingrain core memories. To use the company’s s
Aehr Test Systems (AEHR) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
MARKET PULSE Exelixis Inc. (EXEL) shares fell in the extended session Thursday after the biotech drug maker said a late-stage clinical trial of its kidney cancer drug treatment did not meet its endpoint.
Is Pfizer stock a buy or a sell after the company guided to massive declines for its Covid products? Is PFE stock a buy or a sell?
Skyclarys is the first drug to be approved specifically for the treatment of Friedreich's ataxia and is also Reata Pharmaceuticals' (RETA) first commercial product
Novavax warns of uncertain 2023 outlook as COVID-19 market turns commercial and new CEO calls for pipeline assessment.
Growth stock Novo Nordisk is showing strength after FDA approval of breakthrough oral drug for type 2 diabetes. Shares are in a base.
The jabs could be ready as soon as this summer, one expert tells Fortune.
Eli Lilly said it would limit out-of-pocket expenses at $35 a month for insulin users with commercial insurance and the uninsured.
Oragenics Inc (NYSE: OGEN) entered into an exclusive global license agreement with Inspirevax Inc for its novel intranasal mucosal adjuvant, BDX301, to develop NT-CoV2-1, Oragenics' lead intranasal COVID-19 vaccine candidate. Under the exclusive licensing agreement, Oragenics will pursue the development of NT-CoV2-1 with Inspirevax's BDX301 intranasal mucosal adjuvant. The companies will form a Joint Development Committee (JDC) to oversee the development efforts collaboratively. Oragenics will m
Merck & Co Inc's (NYSE: MRK) Phase 3 KEYNOTE-671 trial investigating Keytruda met one of its dual primary endpoints, event-free survival (EFS), as a perioperative treatment regimen for patients with resectable stage II, IIIA, or IIIB non-small cell lung cancer (NSCLC). A perioperative treatment regimen includes treatment before surgery (neoadjuvant) and continued after surgery (adjuvant). The trial will continue to evaluate the other dual primary endpoint of overall survival (OS). Also Read: Mer
Eli Lilly announced a 70% price cut for most of its insulins Wednesday in a move its CEO described as "aggressive." Eli Lilly stock jumped.
The FDA approved Reata Pharmaceuticals Inc's (NASDAQ: RETA) Skyclarys (omaveloxolone) for Friedreich's ataxia in adults and adolescents aged 16 and older. With this approval, the FDA granted a rare pediatric disease priority review voucher. The company says Skyclarys is the first therapy specifically indicated for Friedreich's ataxia. Related: Why Reata Pharmaceuticals Shares Are Falling Monday? Friedreich's ataxia is an ultra-rare, inherited neurodegenerative disorder typically diagnosed during
Everybody knows now, the energy sector was the place to be last year as the segment was an outlier and one of the few to sidestep 2022’s market carnage. Fueled by rising energy prices amidst Russia’s invasion of Ukraine, overall, energy stocks significantly beat the market. For those mourning a missed opportunity, ‘Shark Tank’ star Kevin O’Leary thinks opportunities in the segment are still abundant. “I love energy. Everybody hates energy… Go where people hate it. Energy is the driving pivot.” O
Marvell (MRVL) delivered earnings and revenue surprises of 0% and 1.31%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?
Stocks moving in after-hours: C3.ai, Dell, Costco, Nordstrom
Sorrento Therapeutics (SRNEQ) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.